ML22012A065

From kanterella
Jump to navigation Jump to search
Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Emerging Radiopharmaceutical Therapy Knowledge Requirements in Theranostics, Draft Report, September 20, 2021
ML22012A065
Person / Time
Issue date: 09/20/2021
From:
Office of Nuclear Material Safety and Safeguards
To:
Valentin-Rodriguez C
References
Download: ML22012A065 (5)
v • d • e


Text

U.S. Nuclear Regulatory Commission Advisory Committee on the Medical Uses of Isotopes

Subcommittee on Emerging Radiopharmaceutical Therapy Knowledge Requirements in Theranostics

Draft Report Submitted on September 20, 2021

Subcommittee Members:

Vasken Dilsizian, M.D.

Ronald Ennis, M.D.

Hossein Jadvar, M.D., PhD (Chair)

Josh Mailman Michael OHara, PhD Zoubir Ouhib

NRC Staff Resource: Maryann Ayoade

Subcommittee Charge:

The Subcommittee was formed in May 2021, by Dr. Darlene Metter, Chair of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) to:

  • To outline the knowledge and specific or specialized practice or policy requirements needed for the safe use and handling of emerging radiopharmaceu ticals in theranostics.
  • Provide considerations and recommendations to staff.

The Subcommittee reviewed the relevant literature (see referenc e section) and met virtually four times in July and August 2021 to discuss the charge and propose several considerations in consultation with the NRC staff.

==

Introduction:==

Theranostics is the systemic integration of diagnostic tools (e.g., nuclear imaging) and therapeutic agents (e.g., radiopharmaceuticals) targeted to the same (or similar*) biomolecule (or physiologic parameter*). This concept is the fundamental f oundation for precision medicine that has advanced considerably in view of our enhanced understa nding of biology, developments in diagnostic technologies, and expansion of thera peutic options. Precision (or personalized) medicine is hoped to improve patient outcome. Wh ile theranostics may be applied to a variety of diseases, cancer has been the primary f ocus in this field (1-4).

Theranostics is a recent term, but it has long been a major pla yer in the history of nuclear medicine, and the list and interest in use of theranostics have been increasing. Early example of theranostics dates back to 1941 when Dr. Saul Hertz from Mas sachusetts General Hospital, in Boston, MA, treated a patient with Graves disease realizing that radioiodine can target the thyroid tissue based on the basic knowledge that thyroid gland concentrates iodine.

The list below are the currently clinically available theranost ics imaging-therapy companion agents, with the biological and disease targets shown in the pa renthesis:

  • 123I/131I (NaI symporter; thyroid)
  • 111In-/90Y-ibritumomab (anti-CD20; lymphoma)
  • 18F-NaF/99mTc-MDP; 223RaCl2 (osteoblastic metastasis; mCRPC)*
  • 123I-/131I-MIBG (norepinephrine transporter; pheochromocytoma, paragangl ioma)

neuroendocrine tumors

NaI=sodium iodide, CD20=cluster of differentiate 20, mCRPC=meta static castration-resistant prostate cancer, NaF=sodium fluoride, MAA=macroaggregated album in, MDP=methyl diphosphonate, MIBG=meta-iodobenzylguanidine, DOTA= 1,4,7,10-tetraazacyclododecane-N,N,N,N-tetraacetic acid, DOTATOC=DOTA-d-Phe1-Tyr3-octreoti de, DOTATATE= DOTA-DPhe1,Tyr3-octreotate

In the near future, theranostics based on prostate specific mem brane antigen (PSMA) will be available clinically for the imaging evaluation of prostate can cer (initial staging, biochemical recurrence) and radioligand therapy of metastatic castration-re sistant prostate cancer. The imaging agents 68Ga-PSMA-11 and 18F-DCFPyL (PylarifyTM) were approved by the FDA in December 2020 and May 2021, respectively. The favorable result s of the randomized phase III VISION clinical trial on the therapy companion - 177Lu-PSMA-617 - has recently been published in the New England Journal of Medicine facilitating an anticipa ted FDA approval within Q1 of 2022 (5).

Additional theranostics pairs are in the horizon within the nex t 7 years. These include the following companion agents with the biological and disease targ ets shown in the parenthesis:

  • 225Ac-/227Th-PSMA (alpha RLT; mCRPC)
  • 68Ga-/177Lu-NeoB (GRPR; solid tumors)
  • 68Ga-/177Lu-FAPI (fibroblast activation protein; multiple cancers)
  • 89Zr-/177Lu-girentuximab (carbonic anhydrase IX; clear cell RCC)
  • 68Ga-/177Lu-FF58 (integrin a3b5; GBM)
  • 18F-/131I-PARPi (DNA repair enzyme Poly-(ADP ribose) polymerase 1; mult iple cancers)

RLT=radioligand therapy, GRPR=gastrin-releasing peptide recepto r, FAPI=fibroblast activated protein inhibitor, RCC=renal cell carcinoma, GBM=glioblastoma m ultiforme

Challenges:

Despite being a rapidly developing field, theranostics faces se veral challenges that will need to be addressed adequately in order for it to be fully integrated into clinical medicine (3).

  • Technical Challenges:

Need for standardized and efficient protocols; formation of int erdisciplinary teams; incorporation into clinical guidelines; education and training.

  • Economic challenges:

Investment into supporting the supply chain for a steady pipeli ne of radioisotopes relevant to theranostics; sufficient reimbursement; comparative cost-utility analysis; Research and Development funding.

  • Biomedical Challenges:

Additional basic science, pre-clinical, first-in-human, and lar ge prospective clinical trials; evaluation of single, tandem, and combination therapies; develo pment of new applications in oncology and non-oncology arenas.

Subcommittee Specific Comments:

1) Radiopharmaceutical (RPT) Healthcare Team:

Depending upon the therapy, the healthcare team administrating the RPT dose may consist of the Authorized User (AU) with appropriate training i n theranostics, Certified Nuclear Medicine Technologist (CNMT), Registered Nurse, Radiati on Safety Officer (RSO), and Medical Physicist (if available/applicable).

2) Authorized User responsibilities:

AU must be present at the time of dose administration; AU is re sponsible for patient concerns related to RPT, including radiation induced injuries; AU is encouraged to avail themselves of all the latest training information for each new theranostics as they emerge.

3) Radiation safety issues:

Non-radiation workers of the healthcare team (e.g. oncology nur se) participating in the procedure may need to wear radiation badges for monitoring as d etermined by the RSO; therapy should be done in a dedicated and regulatory-approved r oom appropriate for radioisotope administrations (see Fig. 1); extravasation; patie nt release criteria (these issues are addressed by other ACMUI subcommittees).

4) Regulatory issues:

Radioactive waste management (refer to the facility established guidelines and regulations); ensure that emerging theranostics are performed w ithin the regulatory guidelines.

5) Dosimetry:

Dosimetry-based (as opposed to fixed-activity) may play an incr easingly important role (6-10); dosimetry-based approach may optimize patient outcome w hile minimizing radiation toxicity; no randomized controlled trials to provide level 1 evidence for benefits of dosimetry-based approach; research is needed on impact of co mbined other nonradioactive therapy agents on RPT biodistribution and radios ensitivity, standardization across clinics, software and medical physicists, development of robust methodology for challenges of surrogate-imaging, microscale rad iation effect and daughter distribution (relevant for alpha particles), and resea rch on potential patient benefit versus cost and complexity of logistics; as relevant da ta becomes mature, AUs should stay abreast of developments in dosimetry.

6) Other relevant issues:

Outreach to AUs, healthcare providers, and patients to promote accurate information about safety and efficacy of theranostics (11).

Fig. 1. An illustrative example of a Radiopharmaceutical Therapy clini c room; an attached bathroom is to the left of the picture (not shown).

References:

(1) Jadvar H, et al. Radiotheranos tics in Cancer Diagnosis and Management. Radiology 2018; 286:388-400.

(2) Turner JH, et al. An Introduction to the Clinical Practice of Theranostics in Oncology.

Br J Radiol 2018; 91:20180440.

(3) Herrmann K, et al. Radiotheranostics: A Roadmap for Future Development. Lancet Oncol 2020; 21:e146-e156.

(4) Gomes Marin JF, et al. Theranostics in nuclear medicine: Em erging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncolo gy. Radiographics 2020; 40:1715-1740.

(5) Sartor O, et al. Lutetium-177-PSMA-617 for Metastatic Castr ation-Resistant Prostate Cancer. N Engl J Med 2021; 385:1091-1103.

(6) Sgouros G, et al. Dosimetry for Radiopharmaceutical Therapy. Semin Nucl Med 2014; 44:172-178.

(7) Lassmann M, et al. The Relevance of Dosimetry in Precision Medicine. J Nucl Med 2018; 59:1494-1499.

(8) Divgi C, et al. Overcoming Barriers to Radiopharmaceutical Therapy (RPT): and Overview from the NRG-NCI Worki ng Group on Dosimetry of Radiopharmaceutical Therapy. Int J Radiat Biol 2021; 109:905-912.

(9) Roncali E et al. Overview of the First NRG Oncology-Nationa l Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. J Nucl Med 2021; 62:1133-1139.

(10) SNMMI 177Lu Dosimetry Challenge 2021. J Nucl Med 2021; 62:10N.

(11) SNMMI Theranostics Video: https://www.youtube.com/watch?v=Bb8Ts5HWS40

Respectfully Submitted on September 20, 2021 Emerging RPT Knowledge Requirements in Theranostics Subcommitte e Advisory Committee on the Medical Uses of Isotopes (ACMUI)

U.S. Nuclear Regulatory Commission (NRC)

Retrieved from "https://kanterella.com/w/index.php?title=ML22012A065&oldid=3737910"